Clinical effectiveness and tolerability of Celery seed and Boswellia serrata extract in osteoarthritis

Abstract

Background: Osteoarthritis (OA) is a common chronic articular degenerative disease marked by articular cartilage degradation, synovial inflammation/immunity, and subchondral bone lesion, among other symptoms. The disease affects 2–6% of the global population, and its prevalence increases with age, reaching 40% in people over the age of 70. Recently, there has been a surge of interest in using nutraceuticals to treat or prevent OA. Celery seed extract & Shallaki extracts (Boswellia serrata) effectively prevent cardiovascular disease, urinary tract infection, gout, and improve blood pressure. Experimental results indicate that both these extracts have anti-inflammatory properties. Aim: The current real-world evidence study was conducted to investigate the effectiveness of Celeract Advance Tablet in OA patients. Methods: A total of 1236 patients were enrolled in the study. All patients received Celeract Advance Tablet for 90 days. Clinical assessment of symptoms included palpation tiredness, mobility limitation, joint crepitus, swelling and redness. Osteoarthritis symptoms were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Total European Quality of Life–5 Dimensions and visual analogue scale (VAS). Results: After 90 days treatment with Celeract Advance Tablet, WOMAC score reduced significantly from 62.64 + 20.47 to 17.22 + 17.59 (p< 0.05). For Total European Quality of Life–5 Dimensions (EQ-5D) score significantly improved from 38.76 + 8.10 to 69.13 + 8.60 (p< 0.05). From the baseline, 78.35% improvement in EQ-5D was observed in patients treated for three months. After 90 days, VAS score for pain significantly reduced from 8.07 + 5.38 to 1.78 + 4.46 (P< 0.05) after 90 days in OA patients. No major adverse reactions were reported. Conclusion: The current study revealed that the Celeract Advance tablet effectively improves joint pain, stiffness, physical function and quality of life in OA patients.